ClinicalTrials.govpublic full text
Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)
non-alcoholic steatohepatitis, eyp001 (vonafexor), liver diseases, non-alcoholic fatty liver disease, nash, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 870936
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.